Case Series Report of a Linezolid-Containing Regimen for Extensively Drug-Resistant Tuberculosis*

Condos, Rany; Hadgiangelis, Nicos; Leibert, Eric; Jacquette, Germaine; Harkin, Timothy J.; Rom, William N.

doi:10.1378/chest.07-1988

Cited by 94 publications

(61 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results regarding the efficacy and good tolerance of linezolid is very different to other experiences in India, where the use of linezolid was not associated with any difference in treatment outcome and where 61% of the patients had major adverse reactions [13]. On the contrary, CONDOS et al [29] achieved favourable outcomes in 50% of their XDR-TB patients by using linezolid systematically in all their patients. It is also possible that linezolid may had contributed to the good outcomes (57% favourable outcome) achieved by EKER et al [30] in Germany using linezolid in 71.4% of their XDR-TB patients.…”

Section: Discussioncontrasting

confidence: 99%

“…In spite of the excellent pharmacological properties against M. tuberculosis discovered .10 yrs ago [27] and the good results communicated in some studies [12,28,29], the findings of the recent multinational study of MIGLIORI et al [11], addressing the assessment of linezolid safety, tolerability and efficacy in MDR-TB patients, were a little disappointing. The conclusions of the study by MIGLIORI et al…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India

Singla¹,

Caminero²,

Jaiswal³

et al. 2011

Eur Respir J

View full text Add to dashboard Cite

Linezolid is identified as an effective drug with which to treat patients failing multidrug-resistant (MDR)-tuberculosis (TB) treatment. However, cost and safety are the concerns. In India, the average price of a 600-mg pill of linezolid is less than one US dollar, much cheaper than most of the third-line drugs.A prospective study of 29 MDR-TB treatment failure patients (16 with laboratory-proven extensively drug-resistant (XDR)-TB and the remaining 13 with MDR-TB with resistance to any quinolone but sensitive to injectables) was carried out in Delhi, India. All patients received daily unsupervised therapy with linezolid, one injectable agent, one fluoroquinolone and two or more other drugs.Patients received a median of six anti-mycobacterial agents. Besides linezolid, capreomycin, moxifloxacin, levofloxacin and amoxycillin-clavulanic acid were used in 41.4%, 58.6%, 41.4%, and 79.3% of patients. Out of a total of 29 patients, 89.7% patients achieved sputum smear and culture conversion; 72.4% showed interim favourable outcome; 10.3% died, 6.8% failed and 10.3% patients defaulted. Linezolid had to be stopped in three (10.3%) patients due to adverse reactions. The outcome of treatment of 16 XDR-TB patients was comparable to the other 13 MDR-TB patients.Linezolid is an effective, cheap and relatively safe drug for patients failing MDR-TB treatment, including those with confirmed XDR-TB.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India

Singla¹,

Caminero²,

Jaiswal³

et al. 2011

Eur Respir J

View full text Add to dashboard Cite

show abstract

“…Of the full-text articles reviewed, two studies were excluded as they included patient data reported in subsequent studies. 18,19 Study characteristics for the 11 included studies are summarised in Table 1. [10][11][12][20][21][22][23][24][25][26][27] A total of 218 patients received linezolid, of whom 148 had evaluable outcomes; the remainder were reported to have been still receiving treatment at the time of publication.…”

Section: Resultsmentioning

confidence: 99%

Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis [Review article]

Cox

Ford

2012

int j tuberc lung dis

127

View full text Add to dashboard Cite

“…The clinical use of linezolid in the treatment of TB, however, is limited to five studies of patients with MDR-TB (13)(14)(15)(16)31). In these studies, linezolid was used in combination with other drugs and therefore its bacteriologic activity was not directly demonstrable.…”

Section: Discussionmentioning

confidence: 99%

Early and Extended Early Bactericidal Activity of Linezolid in Pulmonary Tuberculosis

Dietze

Hadad

McGee

et al. 2008

Am J Respir Crit Care Med

148

View full text Add to dashboard Cite

Rationale: Linezolid, the first oxazolidinone approved for clinical use, has effective in vitro and promising in vivo activity against Mycobacterium tuberculosis. Objectives: To evaluate the early and extended early bactericidal activity of linezolid in patients with pulmonary tuberculosis.Methods: Randomized open label trial. Thirty patients with newly diagnosed smear-positive pulmonary tuberculosis (10 per arm) were assigned to receive isoniazid (300 mg daily) and linezolid (600 mg twice daily or 600 mg once daily) for 7 days. Sputum for quantitative culture was collected for 2 days before and then daily during 7 days of study drug administration. Bactericidal activity was estimated by measuring the decline in bacilli during the first 2 days (early bactericidal activity) and the last 5 days of study drug administration (extended early bactericidal activity). Measurements and Main Results:The mean early bactericidal activity of isoniazid (0.67 log 10 cfu/ml/d) was greater than that of linezolid twice and once daily (0.26 and 0.18 log 10 cfu/ml/d, respectively). The extended early bactericidal activity of linezolid between Days 2 and 7 was minimal. Conclusions: Linezolid has modest early bactericidal activity against rapidly dividing tubercle bacilli in patients with cavitary pulmonary tuberculosis during the first 2 days of administration, but little extended early bactericidal activity. Clinical trial registered with www.clinicaltrials.gov (NCT00396084).

show abstract

Case Series Report of a Linezolid-Containing Regimen for Extensively Drug-Resistant Tuberculosis*

Cited by 94 publications

References 20 publications

Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India

Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India

Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis [Review article]

Early and Extended Early Bactericidal Activity of Linezolid in Pulmonary Tuberculosis

Contact Info

Product

Resources

About